ZIOP traded at a 52wks H as it went easily through the resistance from its Aug 7 H of $2.25 <g>
The stock is still up 19.43% on volume of > 361,700 about 8x its ADV
bigcharts.marketwatch.com
Earlier this month it raised $5.05M in a private placement and it also presented at Rodman & Renshaw 11th Annual Healthcare Conference on Sep 10
ZIOP is currently focused on 3 clinical programs:
Palifosfamide, or ZIO-201 for treating sarcoma, lymphoma, testicular, and other cancers.It delivers only the cancer fighting component of ifosfamide and is expected to overcome the resistance seen with ifosfamide and cyclophosphamide.It also doesn't have the toxic metabolites of ifosfamide.It is on a PII to treat unresectable or metastatic soft tissue sarcoma.
Indibulin,or ZIO-301 is an oral tubulin binding agent that targets both mitosis and cancer cell migration.It's expected benefits, besides oral dosing, is that it has no neuropathy and minimal overall toxicity.It is in several PIs in cancer patients as a single agent and in combination with other drugs.
Darinaparsin, or ZIO-101 is an organic arsenic being developed for the treatment of various hematologic and solid cancers.It is considerably less toxic than inorganic arsenic,particularly with regard to cardiac toxicity.It is in PI and PII for solid tumors and hematological Cas.Ther have been some favorable results on trials with its IV-administration in lymphoma,that were reported at ASCO in May.The oral form reportedly is active and well tolerated.
ZIOP has been trimming its loss in the last 4Qs.It has NSLTD, the ACTAY is $3, but with some good news it seems that the stock could get to the $4 level.<g>
bigcharts.marketwatch.com
Bernard |
